LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors
A primary outcome measure for phase 1 of the trial is determining the safety of oral LOXO-292.
CNS Cancers
Computer-Assisted Diagnosis Aids Detection of Glioma Growth
Computer-assisted diagnosis (CAD) can help physicians detect growth of low-grade gliomas.
Entrectinib Shows Activity in Pediatric Brain Tumors and Other Solid Tumors
Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
Phase 3 Study of Investigative Glioblastoma Tx Halted
AbbVie has halted enrollment in all ongoing studies of depatuxizumab mafodotin, after an Independent Data Monitoring Committee (IDMC) recommended a phase 3 study of the treatment be stopped due to a lack of survival benefit.
Immunotherapy in Glioblastoma: Peaks and Pits
New studies in glioblastoma highlight how PD-1 inhibitors could simultaneously prompt an immune response and steer the selection of tumor clones that evade immune recognition.
Liquid Biopsy of Cerebrospinal Fluid Provides Genomic Info on Brain Tumors
Clinical application of cerebrospinal fluid ctDNA analysis remains unclear.
Proteomics Study Reveals New Medulloblastoma Subtypes and Potential Novel Treatment Targets
Genomic and proteomic studies of medulloblastoma samples helped researchers characterize new cancer subtypes and targets.
Where Have All the T Cells Gone?
New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors.
Iobenguane I 131 First FDA-Approved Drug For Pheochromocytoma or Paraganglioma
The FDA based its approval on findings from a single-arm phase 2 study, in which researchers treated 68 patients with iobenguane I 131 intravenous injection.
Carboxyamidotriazole Orotate With Temozolomide May Be Active Against Glioblastoma
EGFR-amplified tumors had a high rate of response.
Next post in Brain Cancer
